Wegovy approved for cutting cardiovascular disease risk The TGA has approved semaglutide (sold as Wegovy) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in overweight and obese adults.
2024’s top general practice stories From Wegovy and Mounjaro, to tongue cancer, RSV, and vitamin B toxicity, what were the stories most read by GPs this year?
Ozempic shortage extended The manufacturer has informed the TGA that supply will be limited until 31 December 2025, with GPs labelling it an ‘ongoing disappointment’.
Study compares Mounjaro to Wegovy for weight loss A new clinical trial, sponsored by the manufacturer, found Mounjaro led to greater weight loss, but GPs warn of its ‘risks of biases’.
TGA urges ‘extreme caution’ amid fake Ozempic pen imports GPs are being warned to lookout for the counterfeit pens and are urged to inform their patients, with one person already suffering life-threatening complications.
Study links semaglutide and suicidal ideation risk There are calls for urgent investigation into its impact on mental health, but GPs are urging caution when interpreting the research.
Wegovy launches in Australia The manufacturer assured GPs supply planning has been its priority amid critical Ozempic shortages, but concerns remain over Wegovy’s availability.
TGA threatens illegal semaglutide promoters with jail, $1m fines Advertisers and social media influencers have been warned against publicly spruiking the drug for the purposes of weight loss.
Diabetes medication shortage worsens There is not expected be enough dulaglutide in Australia to fill all prescriptions for type 2 diabetes patients until at least early 2023, the TGA has warned.